A biopharmaceutical company developing novel therapeutics to address unmet medical needs in the treatment of cancer. The company is focused on developing, using, manufacturing, commercializing, sublicensing and selling clinical and post-clinical small molecule drug programs and pre-clinical bioconjugation and next-generation ADC platforms, including SMDCs targeting advanced solid tumors. Based in Delaware.